A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Cirrhosis Clinical Trial

Official title:

A Phase I, Open-label, Pharmacokinetic Study of TVB-2640 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05835180
• Other study ID #: SB2640-CLIN-009
• Status: Completed
• Phase: Phase 1
• Start date: May 1, 2023
• Est. completion date: December 18, 2023

Study information

• Verified date: December 2023
• Source: Sagimet Biosciences Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this phase 1 study is to assess the pharmacokinetics, safety and tolerability following multiple oral doses of TVB-2640 in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with normal hepatic function.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: December 18, 2023
• Est. primary completion date: December 18, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Key Inclusion Criteria:

Subjects must satisfy all of the following criteria at the Screening visit unless otherwise stated: All Subjects

• Males or females, of any race, between 18 and 75 years of age, inclusive.
• Body mass index between 18.0 and 42.0/45.0 kg/m2 (inclusive; up to 42.0 kg/m2 for subjects without ascites and 45.0 kg/m2 for subjects with ascites)
• Females will not be pregnant or lactating, and females of childbearing potential (premenopausal females who are anatomically and physiologically capable of becoming pregnant following menarche) and males will agree to use contraception as detailed in the protocol. Subjects with Hepatic Impairment Only
• Documented chronic stable liver disease; diagnosis of cirrhosis due to parenchymal liver disease. T
• Subjects with mild, moderate, or severe hepatic impairment may have medical findings consistent with their hepatic dysfunction.
• Non-hepatic, abnormal clinical laboratory evaluations must not be clinically relevant.
• Currently on a stable medication regimen; Concomitant medications administered within 30 days prior to the first dose administration (Day 1) must be approved by the Investigator (or designee), Sponsor, and the Medical Monitor.
• Anemia secondary to hepatic disease will be acceptable if hemoglobin > 9 g/dL and anemia symptoms are not clinically significant as judged by the Investigator (or designee) and the Medical Monitor. Subjects must have a platelet count = 35 × 109 platelets/L for mild and moderate hepatic impairment subjects and = 30 × 109 platelets/L for severe hepatic impairment subjects.
• Subjects with diabetes mellitus may be included, provided the subjects have:

1. Hemoglobin A1c values = 9.0% at Screening. Subjects with values outside this range may be allowed by the Medical Monitor on a case-by-case basis. Medications for the treatment of diabetes mellitus must be reviewed and approved by the Investigator (or designee), Medical Monitor, and Sponsor. Key Exclusion Criteria: Subjects will be excluded from the study if they satisfy any of the following criteria at the Screening visit unless otherwise stated: All Subjects

• Significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
• History of corneal edema, keratitis, xerophthalmia (dry eye), or other corneal abnormalities. Subjects may wear contact lenses during the study with the exception of the day of dosing (Days 1 to Day 4).
• History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (except uncomplicated appendectomy, hernia repair, and cholecystectomy will be allowed; bariatric surgery will not be allowed).
• Ventricular dysfunction or history of risk factors for Torsade de Pointes. Subjects will be excluded if there is a family history of long QT syndrome.
• Evidence of hepatorenal syndrome and Cockcroft-Gault estimated creatinine clearance (CrCl) = 60 mL/min/1.73 m2 for mild and moderate hepatic impairment subjects, = 50 mL/min/1.73 m2 for severe hepatic impairment subjects or clinically significant abnormal sodium and potassium levels, as determined by the Investigator (or designee), at Screening or Check-in (Day 1).
• Use or intended use of any medications/products known to alter drug absorption, metabolism, or elimination processes.
• Use of any strong inhibitors or inducers of cytochrome P450 (CYP)2C9 or CYP3A4/5, or inhibitors of CYP3A4 within 30 days prior to first dose administration (Day 1).
• Alcohol consumption of > 21 units per week for males and > 14 units for females.
• Positive urine drug screen
• Positive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) polymerase chain reaction (PCR) test at Screening and Check-in (Day -1), history of hospitalization for coronavirus disease-2019 (COVID-19), or history of use of oxygen due to COVID-19. Note that previous COVID-19 infection alone is not exclusionary and vaccination against SARS-CoV-2 is allowed but must be documented.

Related Conditions & MeSH terms

• Cirrhosis
• Fatty Liver
• Fibrosis
• Hepatic Impairment
• Liver Diseases
• Non-alcoholic Fatty Liver Disease
• Non-alcoholic Steatohepatitis

Intervention

Drug:
• TVB-2640 - 50 mg
TVB-2640 -50 mg administered orally once daily

Locations

Country	Name	City	State
Hungary	Geza Lakner	Kistarcsa
United States	Thomas C. Marbury	Orlando	Florida
United States	Eric J. Lawitz, MD	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Sagimet Biosciences Inc.

Countries where clinical trial is conducted

United States,  Hungary, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total TVB-2640 plasma concentration-time (AUC) at steady state	Total TVB-2640 plasma concentration-time curve during a dosing interval at steady-state	Day 4
Primary	Unbound TVB-2640 plasma concentration-time (AUC) at steady state	Unbound TVB-2640 plasma concentration-time curve during a dosing interval at steady-state	Day 4
Primary	Maximum plasma concentration (Cmax) for total TVB-2640 at steady state		Day 4
Primary	Maximum plasma concentration (Cmax) for unbound TVB-2640 at steady state		Day 4
Primary	incidence and severity of AEs		Screening to Day 7